Prolight Diagnostics publishes half-year report, 2023
Financial overviewSecond quarter, 1 April – 30 June, Q2 2023 Group Net sales amounted to 0 (0). Other operating income amounted to kSEK 101 (2,311). The profit after tax amounted to kSEK -8,033 (-7,055). Earnings per share before and after dillution: SEK -0.03 (-0.03). Cash flow from current operations was kSEK -8,571 (-10,210). First half-year, […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, a first summary of the Congress Annual Scientific Meeting + Clinical Lab Expo in Anaheim, USA is given. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics, together with […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, you can read about the launch of the company’s new website and that Prolight Diagnostics is now present at the 2023 AACC Annual Scientific Meeting + Clinical Lab Expo in the USA. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics […]
Prolight Diagnostics showcases breakthrough POC technology at the AACC Annual Scientific Meeting & Clinical Lab Expo
Prolight Diagnostics (“Prolight”) announced today that it will showcase the company’s digital single molecule counting Point-of-Care (POC) system, with high-sensitive troponin capabilities, at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Anaheim, CA, July 23–27. “For the first time we will showcase a concept of our point-of-care (POC) […]
Prolight Diagnostics shows proof-of-performance for high-sensitive troponin
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance on its single molecule detection system to reproducibly detect low levels of the troponin protein. These results pave the way for early detection and rule-out of heart attack, which could reduce healthcare costs and improve the quality of […]
BioStock Life Science Spring Summit with Prolight Diagnostics
Do not miss Prolight Diagnostics’s presentation at the BioStock Life Science Spring Summit, today May 30 at 10.20. The event starts at 10.00. – see the full programme on BioStock’s website (https://www.biostock.se/en/biostock-life-science-summit-may-2023/) or YouTube channel (https://www.youtube.com/channel/UCHXuEgaQtQHZtLCvCJqkT-Q). CEO Ulf Bladinwill present Prolight Diagnostics at the BioStock Life Science Spring Summit (https://www.biostock.se/en/biostock-life-science-summit-may-2023/), starting at 10.20. This is a press release from BioStock – Connectin Innovation […]
Prolight Diagnostics publishes quarterly report Q1, 2023
Financial overviewFirst quarter Q1 2023 Group(figures in brackets only refer to March 2022 as the group was formed on 1 March 2022) Net sales amounted to 0. Other operating income amounted toKSEK 39 (1,298). The profit after tax amounted to kSEK –7,580 (-3,675) Earnings per share before and after dilution: SEK-0.03 (-0.02). Cash flow from […]
Annual General Meeting of Prolight Diagnostics AB (publ) on 11 May 2023
The Annual General Meeting (AGM) of Prolight Diagnostics AB (publ) took place on 11 May 2023 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdiagnostics.se. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Prolight Diagnostics submits patent applications for multiplex testing and enhancing dynamic range
Prolight Diagnostics (“Prolight”) today announces that the company’s subsidiary Psyros Diagnostics (“Psyros”) has submitted two priority patent applications covering various aspects of multiplexing capabilities to the Intellectual Property Office in Great Britain. The first application covers various aspects of multiplexing (i.e., detecting several different biomarkers at the same time on a single sample). By using […]
Annual report for 2022
Prolight Diagnostics AB (publ) announces that the annual report for 2022 is now available on the company’s website, https://prolightdiagnostics.se/en/investor-relations/financial-reports/ and in the attached appendix. For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdiagnostics.seTelephone: +46 73 582 39 87Website: www.prolightdiagnostics.se/en/ About UsProlight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible […]
